Ardelyx, Inc.
$6.3
▼
-2.78%
2026-04-21 05:22:01
www.ardelyx.com
NGM: ARDX
Explore Ardelyx, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.59 B
Current Price
$6.3
52W High / Low
$8.4 / $3.21
Stock P/E
—
Book Value
$0.68
Dividend Yield
—
ROCE
-9.92%
ROE
-36.21%
Face Value
—
EPS
$-0.26
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
489
Beta
0.66
Debt / Equity
140.06
Current Ratio
4.32
Quick Ratio
4.11
Forward P/E
11.84
Price / Sales
3.72
Enterprise Value
$1.48 B
EV / EBITDA
-39.16
EV / Revenue
3.65
Rating
Strong Buy
Target Price
$16.1
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Xencor, Inc. | $12.8 | — | $941.6 M | — | -22.77% | -14.07% | $18.69 / $6.92 | $8.84 |
| 2. | Acurx Pharmaceuticals, Inc. | $2.36 | — | $6.79 M | — | -153.59% | -2.71% | $21 / $1.33 | $2.24 |
| 3. | CorMedix Inc. | $7.58 | 3.58 | $584.18 M | — | 23.03% | 66.56% | $17.43 / $6.13 | $5.11 |
| 4. | Palisade Bio, Inc. | $2.5 | — | $414.71 M | — | -13.92% | -24.52% | $2.64 / $0.53 | $0.81 |
| 5. | Intellia Therapeutics, Inc. | $15.21 | — | $1.8 B | — | -59.74% | -53.48% | $28.25 / $6.8 | $5.77 |
| 6. | NewcelX Ltd. | $2.83 | — | $12.13 M | — | 23.66% | 158.49% | $30.8 / $1.83 | $-11.28 |
| 7. | NRx Pharmaceuticals, Inc. | $3.2 | — | $105.82 M | — | 103.85% | 146.18% | $3.84 / $1.62 | $-0.5 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 125.22 M | 110.33 M | 97.66 M | 74.11 M | 116.13 M |
| Operating Profit | 5.1 M | 4.67 M | -14.39 M | -36.35 M | 8.12 M |
| Net Profit | -0.41 M | -0.97 M | -19.08 M | -41.14 M | 4.64 M |
| EPS in Rs | -0 | -0 | -0.08 | -0.17 | 0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 407.32 M | 333.62 M | 124.46 M | 52.16 M |
| Operating Profit | -40.98 M | -27.95 M | -63.28 M | -63.76 M |
| Net Profit | -61.6 M | -39.14 M | -66.07 M | -67.21 M |
| EPS in Rs | -0.25 | -0.16 | -0.27 | -0.27 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 501.6 M | 435.75 M | 297.58 M | 190.07 M |
| Total Liabilities | 334.65 M | 262.46 M | 130.76 M | 91.74 M |
| Equity | 166.95 M | 173.29 M | 166.82 M | 98.33 M |
| Current Assets | 382.32 M | 356.45 M | 246.11 M | 153.6 M |
| Current Liabilities | 88.61 M | 77.83 M | 50.39 M | 65.6 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -42.48 M | -44.81 M | -89.72 M | -70.04 M |
| Investing CF | -8.96 M | -18.32 M | -131.25 M | 18.41 M |
| Financing CF | 54.51 M | 106.59 M | 146.29 M | 75.34 M |
| Free CF | -43.98 M | -45.82 M | -90.06 M | -70.1 M |
| Capex | -1.49 M | -1.01 M | -0.34 M | -0.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 168.06% | 138.61% | — | — |
| Earnings Growth % | 40.76% | 1.7% | — | — |
| Profit Margin % | -11.73% | -53.08% | -128.85% | — |
| Operating Margin % | -8.38% | -50.84% | -122.24% | — |
| Gross Margin % | 84.85% | 85.7% | 92.11% | — |
| EBITDA Margin % | -5.01% | -44.48% | -116.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.